You are here

Home » Content

HEMODİYALİZ ÜNİTEMİZDE SON 10 YILDA DEĞİŞEN ANTİ-HEPATİT C VİRÜS (HCV) PREVALANSI

ANTI-HCV PREVALENC E IN OUR HEMODIALYSIS UNIT DURING LAST 10 YEARS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2000

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
We determined anti-HCV prevalence in 89 hemodialysis patients in our unit and evaluated the relationship with hemodialysis duration and blood transfusion. Also comparing these findings with the results of the studies at 1990 and 1994 in our unit, we detected the changes in anti-HCV prevalence during last 10 years and possible factors in this change. HCV-antibodies were evaluated with third generation enzyme immunoassay method. Mean age of the patients was 46.5=17 (11-75) years. Dialysis duration and transfusion number were 34.2±36.5 months and 5.1±4.9 units, respectively. Anti-HCV prevalence was decreased from 48 % to 29 % (x2= 4.08, p=0.04) from 1990 to 1994 years. Anti-HCV prevalence was decreased to 19.1 % (17 patients) in 2000, but this decrease (from 1994 to 2000) was not statistically significant (x2=1.80, p=0.18). The relationships between anti-HCV positivity and dialysis duration (p=0.005), and transfusion number (p=0.000) were significant. We conclude that anti-HCV prevalence decreased in our unit during last 10 years. The separation of anti-HCV positive and negative machines, the lower transfusion need due to eryhropoietin treatment and strict application of infection control rules may be responsible for this situation.
Bookmark/Search this post with
Abstract (Original Language): 
Ünitemizde hemodiyalize girmekte olan toplam 89 hastada anti-hepatit C virus (HCV) prevalansını belirleyerek hemodiyaliz süresi ve kan transfüzyonu ile ilişkisini inceledik. Ayrıca 1990 ve 1994 yıllarında ünitemizde yapılan iki ayrı çalışmada elde edilen sonuçlarla bulgularımızı karşılaştırarak, ünitemizde son 10yılda anti-HCVprevalansındaki değişmeyi ve bu değişimde etkili olabilecek faktörleri araştırdık. HCV antikorları üçüncü jenerasyon enzim immunoassay yöntemiyle yapıldı. Hastaların yaş ortalaması 46.5±17 yıl (11, 75) idi. Ortalama diyaliz süresi ve transfüzyon sayıları sırasıyla 34.2±36.5 ay, 5.1=4.9 ünite olarak bulundu. Ünitemizde 1990 yılında %48 olan anti-HCV prevalansının 1994 yılında %29'a gerilediği (x =4.08, p=0.04) tespit edildi. 1994'ten 2000 yılına gelindiğinde ise anti-HCV prevalansının % 19.1'e düştüğü ancak bu azalmanın istatistiki olarak anlamlı olmadığı (x=1.80, p=0.18) saptandı. Anti-HCV pozitifliğinin diyaliz süresi (p=0.005) ve transfüzyon sayısı (p=0,000) ile ilişkisi istatistiki olarak anlamlı bulundu. Ünitemizde son 10 yılda anti-HCV prevalansının önemli oranda düştüğü, bu azalmada anti-HCV pozitif ve negatif makinelerin ayrılması, eritropoetin uygulaması nedeniyle kan transfüzyon ihtiyacının azalması yanında evrensel enfeksiyon kontrol kurallarına daha sıkı uyumun etkili olduğu kanaatine vardık.
FULL TEXT (PDF): 
PDF icon pdf_tndt_305.pdf
  • 3
138-142
  • Turkish

REFERENCES

References: 

1. Chan
TM
, Lok ASF, Cheng IKP, Chan RT. Prevalance of hepatitis-C virus infection in hemodialysis patients; a longitudinal study comparing. The result of RNA antibody assays. Hepatology 1993; 17: 5-8.
2. Scneeberger PM, Toonen N, Keur I, van Hemersvelt HW. Infection control of hepatitis C in Dutch dialysis centres. Nephrol Dial Transplant 1998; 13: 3037-3040.
3. Sheu JC, Lee SH, Wang JT, Wang TH, When DS.
Prevalance of anti-HCV and HCV viremia in hemodialysis patients in Taiwan. J Med Virol 1992;
37(2): 108-112.
4. Yap I, guan R, Kang JY, Tay HH, Lee E, Choong L. Seroprevalance of antibodies to the hepatitis C virus in Singapore. Southeast Asian J trop Med Public Health
1991; 22(4): 581-585.
5. Hejjas M, Medgyesi G, Hajnal A. Reactivity of hepatitis C virus antibody among blood donors in Hungary. Orv Hetil 1992; 133(suppl 1): 21-24.
6. Badur S. Ülkemizde viral hepatitlerin durumu. In: Kılıçturgay K (eds), Viral Hepatit'94. Nobel Tip Kitabevi, Istanbul 1994, ss 15-38.
7. Orak A, Karakullukçu F, Müderrisoğlu C. Hemodiyaliz servisi hasta ve personelinde anti-HCV sıklığı: XIX. Ulusal nefroloji kongresi. Kongre Kitabı: Kuşadası 1990:79.
8. Bozfakioğlu S, Ark A, Ökten A ve ark. Hemodiyaliz hastalarında anti-HCV prevalansı ve önemi. XIX. Ulusal nefroloji kongresi. Kongre Kitabı: Kuşadası 1990:95.
9. Arınsoy T, Arık N, Sungur C, Yasavul Ü, Turgan Ç, Çağlar Ş. Hemodiyaliz hastalarında hepatit C virus antikoru. XIX. Ulusal nefroloji kongresi. Kongre
Kitabı:Kuşadası 1990:85.
10. Erdem I, Sayıner AA, Özacar T, Bilgiç A.Transmission risk of hepatitis C and D virus in screened blood units. 11th World Congress of Anaesthesiologists, Sydney,
Australia, 14-20 April, 1996.
11. Akpolat T, Arık N, Günaydın M et al. Prevalance of anti-HCV among haemodialysis patients in Turkey: A multicenter study. Nephrol Dial Transplant 1995; 10: 479-480.
12. Par A. Antibody to hepatitis C virus in Hungary. Lancet
1990; 336: 343-344.
13. Murthy BVR, Pereira BJG. Hepatitis and human immunodeficiency virus infections in end-stage renal disease patients. In: Henrich WL (eds), Principals and practice of Dialysis, second edition, Lippincott,
Williams and Wilkins: 1999; 285-304.
14. Dussol B, Bertheze P, Brunet P, et al. Hepatitis C virus infection among chronic dialysis patient in south of France; A collaborative study. Am J Kidney Dis 1995;
25: 399-404.
15. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ.
The risk of transfusion-transmitted viral infections. The retrovirus Epidemiology Donor study. N Engl J Med
1996; 334: 1685-1690.
16. Tokars JI, Alter MJ, Miller E, et al. Nationale surveillance of dialysis associated diseases in United States-1994. ASAIO J 1997; 43: 108-119.
17. McLaughlin KJ, Cameron SO Good T et al. Nosocomial transmission of hepatitis C virus within a British dialysis
centre. Nephro Dial Transplant 1997; 12: 304-309.
18. Murthy BVR, Pereira BJG. A 1990's perspective of
hepatitis C, human immunodeficiency virus and tuberculosis infections in dialysis patient. Sem Nephrol
1997; 17: 346-363.
19. Pereira BJG, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51: 981-999.
20. Pellerey M, Bergia R, Berto IM, et al. Epidemiology and clinical course in hepatitis C-positive patients treated with dialysis in Piedmonte. (Work group of the RPDT).
Minerva Urol Nefrol 1996:48(1): 13-17.
21. Jadaul M, Cornu C, van Ypersele de Strihou C, Collaborative Group. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a
prospective study. Kidney Int 1993; 44: 1322-1326.
22.
Özero
l İH, Yeksan M, Tamer M ve ark. Kronik hemodiyaliz hastalarında anti-HCV prevalansı. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi 1994; 3:
5-8.
23. Baykan M, Koşar A, Yeksan M ve ark. Hemodiyaliz ünitemizde son 5 yıldaki HCV ve CMV prevalansı. Journal ofTurgut Özal Medical Center 1995; 2(2): 152¬154.
24. Blumberg A, Zehnder C, Burckhardt JJ. Prevention of hepatit C infection in haemodialysis units. A prospective
study. Nephrol dial Transplant 1995; 10(2): 230-233.
141
25. Gili P, Soffritti S, De Paoli Vitali E, Bedani PL. Prevention of hepatit C virus in dialysis units. Nephron 1995;70:301-306.
26. Calabrase G, Vagelli G, Guaschino R, Gonella M. Transmission of anti-HCV within the household of haemodialysis patients. Lancet 1991; 338: 1446.
27. Vagelli G, Calabrese G, Guaschino R, Gonella M. Effect
of HCV patients isolation on HCV infection incidence in a dialysis unit (letter). Nephrol Dial Transplant 1992; 7: 1068-1073.
28. Pinto dos Santos J, Loureiro A, Cendoroglo M, Pereire BJG. Impact of dialysis room and reuse strategies on incidence of HCV infection in hemodialysis units.
Nephrol Dial Transplant 1996; 11: 2017-2022.
29. Choo Q, Kuo G, Weiner AJ, et al. Isolation of a cDNA
clone derived from a blood-borne non-A, non-B viral
hepatitis genomen. Science 1989; 244: 358-362.
30.
Gülteki
n M, Süleymanlar İ, Baykal A ve ark. Hepatit C virusu (HCV) enfeksiyonu tanısında kullanılan çeşitli yöntemlerin değerlendirilmesi. Viral Hepatit dergisi. 1996;(2) 113-118.
31. Valderrabano F, Jones EHP, Mallick NP. Report on management of renal failure in Europe, XXIV, 1993.
Nephrol Dial Transplant 1995; lO(suppl): 1-25.
32.
Myrth
y BVR, Muerhoff AS, Desai SM, et al. Impact of pre-transplantation GB virus (GBV-C) infection on the outcome of renal transplantation. J Am Soc Nephrol
1997; 8: 1164-1173.

Thank you for copying data from http://www.arastirmax.com